BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 30255568)

  • 21. Expression of GITR Enhances Multiple Myeloma Cell Sensitivity to Bortezomib.
    Zhao Y; Zhang K; Li G; Zhang X; Shi D
    PLoS One; 2015; 10(5):e0127334. PubMed ID: 25973846
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BAY-11-7082 induces apoptosis of multiple myeloma U266 cells through inhibiting NF-κB pathway.
    Wang Y; Zhang XL; Sun CM
    Eur Rev Med Pharmacol Sci; 2018 May; 22(9):2564-2571. PubMed ID: 29771406
    [TBL] [Abstract][Full Text] [Related]  

  • 23. DANFIN functions as an inhibitor of transcription factor NF-κB and potentiates the antitumor effect of bortezomib in multiple myeloma.
    Uematsu A; Kido K; Manabe E; Takeda H; Takahashi H; Hayashi M; Imai Y; Sawasaki T
    Biochem Biophys Res Commun; 2018 Jan; 495(3):2289-2295. PubMed ID: 29284118
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of a potent natural triterpenoid inhibitor of proteosome chymotrypsin-like activity and NF-kappaB with antimyeloma activity in vitro and in vivo.
    Tiedemann RE; Schmidt J; Keats JJ; Shi CX; Zhu YX; Palmer SE; Mao X; Schimmer AD; Stewart AK
    Blood; 2009 Apr; 113(17):4027-37. PubMed ID: 19096011
    [TBL] [Abstract][Full Text] [Related]  

  • 25. NF-κB localization in multiple myeloma plasma cells and mesenchymal cells.
    Conticello C; Giuffrida R; Adamo L; Anastasi G; Martinetti D; Salomone E; Colarossi C; Amato G; Gorgone A; Romano A; Iannolo G; De Maria R; Giustolisi R; Gulisano M; Di Raimondo F
    Leuk Res; 2011 Jan; 35(1):52-60. PubMed ID: 20674018
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cancer-selective targeting of the NF-κB survival pathway with GADD45β/MKK7 inhibitors.
    Tornatore L; Sandomenico A; Raimondo D; Low C; Rocci A; Tralau-Stewart C; Capece D; D'Andrea D; Bua M; Boyle E; van Duin M; Zoppoli P; Jaxa-Chamiec A; Thotakura AK; Dyson J; Walker BA; Leonardi A; Chambery A; Driessen C; Sonneveld P; Morgan G; Palumbo A; Tramontano A; Rahemtulla A; Ruvo M; Franzoso G
    Cancer Cell; 2014 Oct; 26(4):495-508. PubMed ID: 25314077
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Norcantharidin enhances bortezomib-antimyeloma activity in multiple myeloma cells in vitro and in nude mouse xenografts.
    Du HF; Yu LJ; Meng YF; Lv HY; Meng J; Song XN; Zhang JQ
    Leuk Lymphoma; 2013 Mar; 54(3):607-18. PubMed ID: 22889356
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current status of bortezomib in the treatment of multiple myeloma.
    Cavo M
    Curr Hematol Malig Rep; 2007 May; 2(2):128-37. PubMed ID: 20425361
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antitumor effects of (S)-HDAC42, a phenylbutyrate-derived histone deacetylase inhibitor, in multiple myeloma cells.
    Bai LY; Omar HA; Chiu CF; Chi ZP; Hu JL; Weng JR
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):489-96. PubMed ID: 21072520
    [TBL] [Abstract][Full Text] [Related]  

  • 30. NF-κB in the crosshairs: Rethinking an old riddle.
    Bennett J; Capece D; Begalli F; Verzella D; D'Andrea D; Tornatore L; Franzoso G
    Int J Biochem Cell Biol; 2018 Feb; 95():108-112. PubMed ID: 29277662
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Blockade of deubiquitinase USP7 overcomes bortezomib resistance by suppressing NF-κB signaling pathway in multiple myeloma.
    Yao Y; Zhang Y; Shi M; Sun Y; Chen C; Niu M; Zhang Q; Zeng L; Yao R; Li H; Yang J; Li Z; Xu K
    J Leukoc Biol; 2018 Dec; 104(6):1105-1115. PubMed ID: 30024656
    [TBL] [Abstract][Full Text] [Related]  

  • 32. KSP inhibitor SB743921 induces death of multiple myeloma cells via inhibition of the NF-κB signaling pathway.
    Song IS; Jeong YJ; Nyamaa B; Jeong SH; Kim HK; Kim N; Ko KS; Rhee BD; Han J
    BMB Rep; 2015 Oct; 48(10):571-6. PubMed ID: 25772758
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The potential utility of sodium valproate as a novel addition to anti-multiple myeloma armamentarium.
    Namazi MR
    Med Hypotheses; 2005; 64(6):1246-7. PubMed ID: 15823734
    [No Abstract]   [Full Text] [Related]  

  • 34. Structure-activity relationships of benzhydrol derivatives based on 1'-acetoxychavicol acetate (ACA) and their inhibitory activities on multiple myeloma cell growth via inactivation of the NF-κB pathway.
    Misawa T; Dodo K; Ishikawa M; Hashimoto Y; Sagawa M; Kizaki M; Aoyama H
    Bioorg Med Chem; 2015 May; 23(9):2241-6. PubMed ID: 25801158
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bavachin induces the apoptosis of multiple myeloma cell lines by inhibiting the activation of nuclear factor kappa B and signal transducer and activator of transcription 3.
    Takeda T; Tsubaki M; Tomonari Y; Kawashima K; Itoh T; Imano M; Satou T; Nishida S
    Biomed Pharmacother; 2018 Apr; 100():486-494. PubMed ID: 29477912
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of expression of nuclear factor kappa B (NF-kappa B) in multiple myeloma: downregulation of NF-kappa B induces apoptosis.
    Ni H; Ergin M; Huang Q; Qin JZ; Amin HM; Martinez RL; Saeed S; Barton K; Alkan S
    Br J Haematol; 2001 Nov; 115(2):279-86. PubMed ID: 11703322
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities.
    Sagawa M; Tabayashi T; Kimura Y; Tomikawa T; Nemoto-Anan T; Watanabe R; Tokuhira M; Ri M; Hashimoto Y; Iida S; Kizaki M
    Cancer Sci; 2015 Apr; 106(4):438-46. PubMed ID: 25613668
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Curcumin ameliorates the in vitro efficacy of carfilzomib in human multiple myeloma U266 cells targeting p53 and NF-κB pathways.
    Allegra A; Speciale A; Molonia MS; Guglielmo L; Musolino C; Ferlazzo G; Costa G; Saija A; Cimino F
    Toxicol In Vitro; 2018 Mar; 47():186-194. PubMed ID: 29223572
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Importin β1 mediates nuclear factor-κB signal transduction into the nuclei of myeloma cells and affects their proliferation and apoptosis.
    Yan W; Li R; He J; Du J; Hou J
    Cell Signal; 2015 Apr; 27(4):851-9. PubMed ID: 25643631
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Monitoring a nuclear factor-κB signature of drug resistance in multiple myeloma.
    Xiang Y; Remily-Wood ER; Oliveira V; Yarde D; He L; Cheng JQ; Mathews L; Boucher K; Cubitt C; Perez L; Gauthier TJ; Eschrich SA; Shain KH; Dalton WS; Hazlehurst L; Koomen JM
    Mol Cell Proteomics; 2011 Nov; 10(11):M110.005520. PubMed ID: 21846842
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.